top of page
Search
MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer
Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of cell therapy pioneer Christine Günther, MD, PhD, as Chief Technology Officer (CTO), effective December 1, 2025. Dr. Günther brings more than 30 years of experience translating regenerative medicine innovations from development to clinical application. Dr. Günther
Dec 18, 20253 min read
MUVON Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Statistically Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
Dec 3, 20254 min read
Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025
Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as...
Jul 1, 20252 min read
MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025
Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the...
Apr 16, 20252 min read
INVEST IN OUR
INNOVATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page